Tomotherapy for Leptomeningeal Metastases

Clinical Trial Description

This is a single-arm, single center, phase II trial to investigate the feasibility and toxicity of tomotherapy for leptomeningeal metastases, which are defined as leptomeningeal metastases with or without brain metatstases. ;

Study Design

See also
Status	Clinical Trial	Phase
Terminated	`NCT05414123` - A Therapy Treatment Response Trial in Patients With Leptomeningeal Metastases ((LM) Using CNSide
Recruiting	`NCT06058988` - Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer	Phase 2
Recruiting	`NCT06399926` - Efficacy and Safety of Intraventricule Pemetrexed Disodium Administered Via Ommaya Reservoir
Not yet recruiting	`NCT06441045` - Double Dose of Third-generation EGFR-TKI Plus Intrathecal Pemetrexed Versus Double Dose of Third-generation EGFR-TKI in Patients With LM Progression Following the Treatment of Routine Dose of Third-generation EGFR-TKI	Phase 2
Recruiting	`NCT04425681` - Osimertinib With Bevacizumab for Leptomeningeal Metastasis From EGFR-mutation Non-Small Cell Lung Cancer	Phase 2
Recruiting	`NCT05598853` - Intrathecal Double Checkpoint Inhibition	Phase 1
Recruiting	`NCT02803619` - A Multi-center Prospective Observational Biomarker Study on EGFRm+ Non-small Cell Lung Cancer Patients With Leptomeningeal Metastasis	N/A
Recruiting	`NCT05746754` - Proton Cranio-spinal Irradiation for Leptomeningeal Metastasis	N/A
Not yet recruiting	`NCT04148898` - Osimertinib With or Without Bevacizumab for EGFR- Mutant Non-small Cell Lung Cancer With Leptomeningeal Metastasis	Phase 2
Completed	`NCT04420598` - DS-8201a for trEatment of aBc, BRain Mets, And Her2[+] Disease	Phase 2
Completed	`NCT02071056` - Circulating Tumor DNA in Cerebrospinal Fluid as an Early Biomarker of Leptomeningeal Metastasis (LM)
Recruiting	`NCT05385185` - Clinical Observation of ICI Combined With Recombinant Human Endostatin on Leptomeningeal Metastasis of Lung Cancer	Phase 2
Terminated	`NCT04729348` - Pembrolizumab And Lenvatinib In Leptomeningeal Metastases	Phase 2
Recruiting	`NCT06304441` - Intra-pemetrexed Plus Third-generation Small Molecule TKI Drugs (e.g. 'Osimertinib') Versus Third-generation Small Molecule TKI Drugs Alone for Leptomeningeal Metastasis From Epidermal Growth Factor Receptor Mutation-Positive Non-Small-cell Lung Cancer	N/A
Not yet recruiting	`NCT06296745` - Intrathecal Pemetrexed for Leptomeningeal Metastasis From Lung Adenocarcinoma That Progressed After Osimertinib.	Phase 2
Recruiting	`NCT04778800` - A Dose Exploration Study of Almonertinib for EGFRm NSCLC Patients With Brain/Leptomeningeal Metastasis (ARTISTRY)	N/A
Not yet recruiting	`NCT06282874` - Lorlatinib in Patients With ALK-Positive NSCLC With Brain or Leptomeningeal Metastases	Phase 4
Not yet recruiting	`NCT04356222` - Efficacy and Safety of Durvalumab in Non-Small Cell Lung Cancer With Leptomeningeal Metastasis	Phase 4
Not yet recruiting	`NCT04356118` - Efficacy and Safety of Recombinant Human Endostatin in Non-Small Cell Lung Cancer With Leptomeningeal Metastasis	Phase 4
Not yet recruiting	`NCT06462222` - Immune Checkpoint Inhibitor Combined With Pemetrexed Intrathecal Injection for Leptomeningeal Metastasis From Solid Tumors	Phase 1/Phase 2

NCT number	NCT04178343
Study type	Interventional
Source	Chinese Academy of Medical Sciences
Contact
Status	Completed
Phase	N/A
Start date	September 1, 2014
Completion date	October 24, 2018

Tomotherapy for Leptomeningeal Metastases

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms